Company Page

Siren Biotechnology is developing universal AAV immuno-gene therapy for cancer treatment by combining adeno-associated virus gene therapy with cytokine immunotherapy. The company's platform delivers engineered cytokines directly into tumors using AAV vectors, turning cancer cells into localized drug factories that activate the immune system to destroy tumors. Siren's approach is designed to work across multiple solid tumor types including brain and eye cancers, with the lead program targeting high-grade glioma. The company emerged from stealth in May 2023 and is backed by Founders Fund, Lux Capital, and other prominent investors.

Company Founded in 2020

Healthtech & Biotech